Logo image of ONC.CA

ONCOLYTICS BIOTECH INC (ONC.CA) Stock Fundamental Analysis

TSX:ONC - Toronto Stock Exchange - CA6823108759 - Common Stock - Currency: CAD

1.44  +0.02 (+1.41%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ONC. ONC was compared to 25 industry peers in the Biotechnology industry. ONC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ONC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ONC had negative earnings in the past year.
ONC had a negative operating cash flow in the past year.
ONC had negative earnings in each of the past 5 years.
In the past 5 years ONC always reported negative operating cash flow.
ONC.CA Yearly Net Income VS EBIT VS OCF VS FCFONC.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -159.90%, ONC perfoms like the industry average, outperforming 48.00% of the companies in the same industry.
The Return On Equity of ONC (-485.11%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -159.9%
ROE -485.11%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONC.CA Yearly ROA, ROE, ROICONC.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

ONC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONC.CA Yearly Profit, Operating, Gross MarginsONC.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONC has more shares outstanding
Compared to 5 years ago, ONC has more shares outstanding
Compared to 1 year ago, ONC has a worse debt to assets ratio.
ONC.CA Yearly Shares OutstandingONC.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONC.CA Yearly Total Debt VS Total AssetsONC.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ONC has an Altman-Z score of -33.49. This is a bad value and indicates that ONC is not financially healthy and even has some risk of bankruptcy.
ONC has a Altman-Z score (-33.49) which is in line with its industry peers.
A Debt/Equity ratio of 0.11 indicates that ONC is not too dependend on debt financing.
The Debt to Equity ratio of ONC (0.11) is better than 68.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -33.49
ROIC/WACCN/A
WACCN/A
ONC.CA Yearly LT Debt VS Equity VS FCFONC.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 3.21 indicates that ONC has no problem at all paying its short term obligations.
ONC's Current ratio of 3.21 is fine compared to the rest of the industry. ONC outperforms 72.00% of its industry peers.
ONC has a Quick Ratio of 3.21. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.21, ONC is in the better half of the industry, outperforming 72.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.21
Quick Ratio 3.21
ONC.CA Yearly Current Assets VS Current LiabilitesONC.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ONC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 37.70% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.46%
EPS Next 2Y-1.41%
EPS Next 3Y5.64%
EPS Next 5Y37.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONC.CA Yearly Revenue VS EstimatesONC.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONC.CA Yearly EPS VS EstimatesONC.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONC.CA Price Earnings VS Forward Price EarningsONC.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC.CA Per share dataONC.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.41%
EPS Next 3Y5.64%

More info and screens

0

5. Dividend

5.1 Amount

ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLYTICS BIOTECH INC

TSX:ONC (7/30/2025, 7:00:00 PM)

1.44

+0.02 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners1.52%
Inst Owner ChangeN/A
Ins Owners4.01%
Ins Owner ChangeN/A
Market Cap127.90M
Analysts77.5
Price Target4.67 (224.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.77%
Min EPS beat(2)18.74%
Max EPS beat(2)20.79%
EPS beat(4)3
Avg EPS beat(4)6.82%
Min EPS beat(4)-15.35%
Max EPS beat(4)20.79%
EPS beat(8)5
Avg EPS beat(8)9.08%
EPS beat(12)8
Avg EPS beat(12)7.42%
EPS beat(16)10
Avg EPS beat(16)8.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.84%
PT rev (3m)1.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 19.7
P/tB 19.7
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -159.9%
ROE -485.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.21
Quick Ratio 3.21
Altman-Z -33.49
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y1.46%
EPS Next 2Y-1.41%
EPS Next 3Y5.64%
EPS Next 5Y37.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y43.37%
FCF growth 1Y-4.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.23%
OCF growth 3YN/A
OCF growth 5YN/A